Alimera Sciences (NASDAQ:ALIM) Upgraded to Hold by Zacks Investment Research

Zacks Investment Research upgraded shares of Alimera Sciences (NASDAQ:ALIM) from a sell rating to a hold rating in a research note issued to investors on Thursday morning, Zacks.com reports.

According to Zacks, “Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. “

Other equities research analysts have also recently issued reports about the stock. Craig Hallum began coverage on shares of Alimera Sciences in a research report on Tuesday, May 28th. They issued a buy rating and a $3.00 target price for the company. ValuEngine raised shares of Alimera Sciences from a hold rating to a buy rating in a research report on Thursday, August 1st. Finally, HC Wainwright set a $2.00 target price on shares of Alimera Sciences and gave the stock a buy rating in a research report on Wednesday, September 4th. One research analyst has rated the stock with a hold rating and three have issued a buy rating to the company. The company currently has an average rating of Buy and a consensus price target of $2.00.



NASDAQ:ALIM opened at $0.50 on Thursday. The company has a 50-day moving average price of $0.47 and a 200-day moving average price of $0.84. Alimera Sciences has a 12 month low of $0.32 and a 12 month high of $1.21.

Alimera Sciences (NASDAQ:ALIM) last posted its earnings results on Monday, July 29th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by ($0.03). The firm had revenue of $10.86 million for the quarter, compared to analysts’ expectations of $12.97 million. As a group, research analysts forecast that Alimera Sciences will post -0.16 earnings per share for the current year.

Large investors have recently bought and sold shares of the company. Royce & Associates LP lifted its position in shares of Alimera Sciences by 79.0% in the 1st quarter. Royce & Associates LP now owns 571,275 shares of the biopharmaceutical company’s stock worth $606,000 after purchasing an additional 252,089 shares during the period. B. Riley Wealth Management Inc. lifted its position in shares of Alimera Sciences by 36.7% in the 1st quarter. B. Riley Wealth Management Inc. now owns 139,302 shares of the biopharmaceutical company’s stock worth $148,000 after purchasing an additional 37,396 shares during the period. Knott David M lifted its position in shares of Alimera Sciences by 3.9% in the 1st quarter. Knott David M now owns 402,901 shares of the biopharmaceutical company’s stock worth $427,000 after purchasing an additional 15,000 shares during the period. Renaissance Technologies LLC lifted its position in Alimera Sciences by 13.1% during the 2nd quarter. Renaissance Technologies LLC now owns 1,128,404 shares of the biopharmaceutical company’s stock valued at $1,004,000 after acquiring an additional 130,414 shares during the period. Finally, Tower Research Capital LLC TRC lifted its position in Alimera Sciences by 32,745.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 54,852 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 54,685 shares during the period. 50.39% of the stock is owned by hedge funds and other institutional investors.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.

Read More: Dividend Reinvestment Plan (DRIP)

Get a free copy of the Zacks research report on Alimera Sciences (ALIM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.